Opinion|Videos|June 24, 2024
Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02
Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.
Advertisement
Episodes in this series
- Briefly discuss the potential role of ADCs in NSCLC with non-actionable mutations.
- What is the rationale for use of ADCs in this treatment space?
- What characteristics may allow ADCs to be more advantageous in this treatment space over other traditional chemotherapy and targeted agents?
- Which ADCs are most likely to have potential benefit here and why?
- Please review the rationale and study design for EVOKE-02 and discuss key efficacy and safety data and the implications these findings may have on the treatment landscape. (
Garon, et al. J Clin Oncol, 2022 ;Cho, et al. WCLC 2023 ;Cappuzzo et al. WLC 2024. Efficacy results by histology from the EVOKE-2 study ;ASCO 2024 Patel et al. SG + Pembro in 1L mNSCLC with PD-L1 ≥50%: Cohort A of EVOKE-02) - What do data demonstrateregarding the efficacy of SG + pembro in patients with NSCLC and how does response differ by PD-L1 expression?
- Other key takeaways? What implications could these findings have on clinical practice?
- Which patients stand to benefit the greatest from this treatment approach?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.
Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Phase 3 SAFFRON data support EU and Japanese filings for savolitinib plus osimertinib in EGFR-mutated NSCLC with MET overexpression or amplification.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Cai on the Rationale for Evaluating Rocbrutinib Plus R-CHOP in Non-GCB DLBCL and MCL
4
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
5